Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 5/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | CNOT7 | Q9UIV1 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1945291 | 0.84 | PKM (0.51) | PKMMAPK10TLR7GABRA5GABRA1 | |
| SCHEMBL1946059 | 0.84 | ALDH1A1 (0.51) | TLR7KMT2AMEN1CYP3A4HPGD | |
| SCHEMBL1944136 | 0.82 | HPGD (0.47) | PKMMAPK10TLR7KMT2AMEN1 | |
| SCHEMBL1948074 | 0.76 | ALDH1A1 (0.39) | KMT2AALDH1A1 | |
| SCHEMBL1944502 | 0.74 | ALDH1A1 (0.70) | PKMMAPK10TLR7KMT2AOPRM1 | |
| SCHEMBL1944329 | 0.73 | TLR7 (0.49) | PKMMAPK10TLR7GABRA5GABRA1 | |
| SCHEMBL1944562 | 0.73 | GRIN1 (0.49) | PKMMAPK10TLR7GABRA5GABRA1 | |
| SCHEMBL1946628 | 0.73 | KMT2A (0.54) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL4616203 | 0.73 | KDM4E (0.46) | KMT2ALMNAMEN1CYP1A2CYP3A4 | |
| SCHEMBL6980977 | 0.72 | PKM (0.79) | PKMMAPK10KMT2AOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123280-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8324224-B2 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110257127-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| EP-1444233-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD PALO ALTO INC (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20110130362-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-7795269-B2 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100222300-A1 | A2B Adenosine Receptor Antagonists | GILEAD PALO ALTO, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-7741331-B2 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| WO-2009157938-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING CANCER | CV THERAPEUTICS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009088518-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER | CV THERAPEUTICS, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-6977300-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050261316-A1 | A2B Adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2005-11-24 | — | — | US | disclosed |
| US-20050101778-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2005-05-12 | — | — | US | disclosed |
| US-20050038045-A1 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2005-02-17 | — | — | US | disclosed |
| WO-2004106337-A1 | XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-6825349-B2 | PURINE DERIVATIVES FOR TREATMENT OF GASTROINTESTINAL DISORDERS, IMMUNOLOGICAL DISORDERS, NEUROLOGICAL DISORDERS | CV THERAPEUTICS INC. | 2004-11-30 | — | — | US | disclosed |
| EP-1444233-A2 | A 2B? ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20030229106-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-12-11 | — | — | US | disclosed |
| US-20030139428-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-07-24 | — | — | US | disclosed |
| WO-2003042214-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257127-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | PKM 4312/4885MAPK10 4039/4885TLR7 1542/4885 |
| US-20050038045-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | PKM 4312/4885MAPK10 4039/4885TLR7 1542/4885 |
| US-20050101778-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | PKM 3584/4885MAPK10 3550/4885TLR7 1430/4885 |
| US-20100222300-A1 | A2B Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA1 | PKM 4312/4885MAPK10 4039/4885TLR7 1542/4885 |
| US-20030139428-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | PKM 4408/4885MAPK10 3942/4885TLR7 1381/4885 |
| US-20030229106-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | PKM 4408/4885MAPK10 3942/4885TLR7 1381/4885 |
| US-20050261316-A1 | A2B Adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | PKM 4312/4885MAPK10 4039/4885TLR7 1542/4885 |
| US-20130123280-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | PKM 4312/4885MAPK10 4039/4885TLR7 1542/4885 |
| US-20110130362-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | PKM 4312/4885MAPK10 4039/4885TLR7 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.